{"doi":"10.1001/jamanetworkopen.2022.18794","title":"Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua","abstract":"Importance: The impact of the SARS-CoV-2 pandemic on children remains unclear. Better understanding of the burden of COVID-19 among children and their risk of reinfection is crucial, as they will be among the last groups vaccinated. Objective: To characterize the burden of COVID-19 and assess how risk of symptomatic reinfection may vary by age among children. Design, Setting, and Participants: In this prospective, community-based pediatric cohort study conducted from March 1, 2020, to October 15, 2021, 1964 nonimmunocompromised children aged 0 to 14 years were enrolled by random selection from the Nicaraguan Pediatric Influenza Cohort, a community-based cohort in District 2 of Managua, Nicaragua. Additional newborn infants aged 4 weeks or younger were randomly selected and enrolled monthly via home visits. Exposures: Prior COVID-19 infection as confirmed by positive anti-SARS-CoV-2 antibodies (receptor binding domain and spike protein) or real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 infection at least 60 days before current COVID-19 infection. Main Outcomes and Measures: Symptomatic COVID-19 cases confirmed by real-time RT-PCR and hospitalization within 28 days of symptom onset of a confirmed COVID-19 case. Results: This cohort study assessed 1964 children (mean [SD] age, 6.9 [4.4] years; 985 [50.2%] male). Of 1824 children who were tested, 908 (49.8%; 95% CI, 47.5%-52.1%) were seropositive during the study. There were also 207 PCR-confirmed COVID-19 cases, 12 (5.8%) of which were severe enough to require hospitalization. Incidence of COVID-19 was highest among children younger than 2 years (16.1 cases per 100 person-years; 95% CI, 12.5-20.5 cases per 100 person-years), which was approximately 3 times the incidence rate in any other child age group assessed. In addition, 41 symptomatic SARS-CoV-2 episodes (19.8%; 95% CI, 14.4%-25.2%) were reinfections. Conclusions and Relevance: In this prospective, community-based pediatric cohort study, rates of symptomatic and severe COVID-19 were highest among the youngest participants, with rates stabilizing at approximately 5 years of age. In addition, symptomatic reinfections represented a large proportion of symptomatic COVID-19 cases.","journal":"JAMA Network Open","year":2022,"id":270233,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8623,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":236673,"name":"Ángel Balmaseda","orcid":"0000-0003-1174-4235","position":1,"is_corresponding":false},{"id":390630,"name":"Aaron M. Frutos","orcid":"0000-0001-6948-3918","position":2,"is_corresponding":false},{"id":236668,"name":"Nery Sánchez","orcid":"0000-0002-0070-3895","position":3,"is_corresponding":false},{"id":236669,"name":"Miguel Plazaola","orcid":"0000-0002-4153-2615","position":4,"is_corresponding":false},{"id":236667,"name":"Sergio Ojeda","orcid":"0000-0003-2512-2306","position":5,"is_corresponding":false},{"id":671858,"name":"Saira Saborío","orcid":null,"position":6,"is_corresponding":false},{"id":390629,"name":"Roger López","orcid":"0000-0002-1091-5955","position":7,"is_corresponding":false},{"id":671859,"name":"Carlos Barilla","orcid":null,"position":8,"is_corresponding":false},{"id":934499,"name":"Gerald Vásquez","orcid":null,"position":9,"is_corresponding":false},{"id":934500,"name":"Hanny Moreira","orcid":null,"position":10,"is_corresponding":false},{"id":565277,"name":"Anna Gajewski","orcid":null,"position":11,"is_corresponding":false},{"id":866235,"name":"Lora Campredon","orcid":"0000-0001-5150-6165","position":12,"is_corresponding":false},{"id":671376,"name":"Hannah E. Maier","orcid":"0000-0001-5761-0801","position":13,"is_corresponding":false},{"id":466674,"name":"Mahboob Chowdhury","orcid":null,"position":14,"is_corresponding":false},{"id":901673,"name":"Cristhiam Cerpas","orcid":"0009-0008-9692-5935","position":15,"is_corresponding":false},{"id":236674,"name":"Eva Harris","orcid":"0000-0002-7238-4037","position":16,"is_corresponding":false},{"id":236672,"name":"Guillermina Kuan","orcid":"0000-0002-5251-173X","position":17,"is_corresponding":false},{"id":227052,"name":"Aubree Gordon","orcid":"0000-0002-9352-7877","position":18,"is_corresponding":false},{"id":413550,"name":"John Kubale","orcid":"0000-0001-5571-9774","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T00:27:26.772098Z","pmid":"35759261","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}